Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors

Inclusion Criteria: * Participants with histologically or cytologically confirmed advanced solid tumors harboring a KRAS G12D mutation; * Failed standard therapy, intolerant to standard therapy, or no standard therapy is available; * ECOG Performance Status of 0 or 1; * Adequate organ function Exclusion Criteria: * History of ≥2 primary malignancies within 5 years prior to signing informed consent, except for adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, or other malignancies considered cured; * Primary central nervous system (CNS) tumors * leptomeningeal metastases, brainstem metastases, or spinal cord compression confirmed by imaging (regardless of symptoms) Other inclusion/exclusion criteria may apply.